Publications by authors named "O E Della Pasqua"
Article Synopsis
- The study highlights that body weight and sex can significantly impact how anticancer drugs are processed in the body, yet the extent of these differences remains unclear.
- A systematic review of 112 studies identified significant pharmacokinetic (PK) differences for 14 out of 99 examined anticancer agents, although no studies currently assess how these differences impact drug efficacy or safety.
- The findings suggest that developing sex-specific dosing strategies for anticancer drugs could improve their risk-benefit ratio for patients.
Aims: Our investigation aimed to assess the dose rationale of tramadol in paediatric patients considering the effect of CYP2D6/OCT1 polymorphisms on systemic exposure. Recommendations were made for the oral dose of tramadol to be used in a prospective study in children (3 months to < 18 years old) with chronic pain.
Methods: Intravenous pharmacokinetic and genotype data from neonatal patients (n = 46) were available for this analysis.
Article Synopsis
- The study investigates a new combination therapy for Buruli ulcer, focusing on amoxicillin/clavulanic acid (AMX/CLV) and its effectiveness compared to other antibiotics like rifampicin and clarithromycin.* -
- Methods included in vitro tests to measure antibacterial activity and clinical trial simulations to assess how different dosing regimens would perform in various patient populations.* -
- Results indicated that a targeted weight-based dosing plan for rifampicin, clarithromycin, and AMX/CLV performs better than the standard dosage of AMX/CLV, suggesting a potential enhancement in treatment outcomes with this 4-drug combination.*
Introduction: Although some factors associated with asthma symptom deterioration and risk of exacerbation have been identified, these are not yet fully characterised. We conducted a clinical modelling and simulation study to understand baseline factors affecting symptom control, reliever use and exacerbation risk in patients with moderate-severe asthma during follow-up on regularly dosed inhaled corticosteroid (ICS) monotherapy, or ICS/long-acting beta-agonist (LABA) combination therapy.
Methods: Individual patient data from randomised clinical trials (undertaken between 2001 and 2019) were used to model the time course of symptoms (n = 7593), patterns of reliever medication use (n = 3768) and time-to-first exacerbation (n = 6763), considering patient-specific and extrinsic factors, including treatment.
Effect of Interindividual Variability in Metabolic Clearance and Relative Bioavailability on Rifampicin Exposure in Tuberculosis Patients with and without HIV Co-Infection: Does Formulation Quality Matter?
Pharmaceutics
July 2024
Article Synopsis
- The study investigates how rifampicin (RIF) behaves in the bodies of tuberculosis patients, both with and without HIV, focusing on its metabolite, 25-O-desacetyl-rifampicin (desRIF).
- Researchers analyzed data from 33 TB patients on RIF treatment and found that HIV co-infection does not affect RIF levels in the blood, and desRIF formation does not account for variability in its disposition.
- Results indicated that RIF had lower effectiveness than expected, especially in patients weighing less than 50 kg, suggesting that the formulation of the drug leads to reduced absorption in the body.